menu search

Panbela announces clinical trial with moffitt cancer center for phase i/ii program in stk11 mutant non-small cell lung cancer

MINNEAPOLIS, May 22, 2023 (GLOBE NEWSWIRE) — Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics ...

May 22, 2023, 12:15 pm

Hepion pharmaceuticals’ phase 2 ‘altitude-nash’ trial achieves primary and secondary endpoints, including improvement in liver function and multiple nash biomarkers

– Improvements in physiologic liver function and key NASH biomarkers including ALT, ProC3, PiiINP and...

May 22, 2023, 11:00 am

Fat brands to present at ld micro invitational xiii

Presentation on Tuesday, June 6 at 4: 3 0 PM PT LOS ANGELES, May 22, 2023 (GLOBE NEWSWIRE) -- FAT (Fresh. Authentic....

May 22, 2023, 9:00 am

Innovative industrial properties: don't fall in love with its dividend yields

iiPR has plunged by -31.84% YTD and -74.1% since its peak in November 2021, triggered by the unlikely f...

May 22, 2023, 9:00 am

Canadian pacific kansas city is on the right track

Put majestic forests, hockey, southern BBQ and this year's Super Bowl LVii champ in a blender, and you ...

May 22, 2023, 8:49 am

Actelis to present at the ld micro invitational xiii

FREMONT, Calif., May 22, 2023 (GLOBE NEWSWIRE) -- Actelis Networks, Inc. (NASDAQ: ASNS) (“Actelis” or the “Company”), a market leader in cyber...

May 22, 2023, 8:00 am

Wisa technologies, inc. to present at ld micro invitational xiii

BEAVERTON, Ore.--(BUSINESS WIRE)---- $WISA #WISA--WiSA Technologies, Inc. announces participation in the LD Micro Invitational X...

May 22, 2023, 7:00 am

Jpmorgan forecasts nii to increase to about $84 bln after first republic deal

JPMorgan Chase & Co on Monday forecast full-year net interest income, excluding markets outlook, will increase to about $84 billion due to its acquisi...

May 22, 2023, 6:21 am

Nexcella announces positive nxc-201 clinical results at asgct: 100% overall response rate in darzalex-relapsed/refractory al amyloidosis with zero icans in ongoing nexicart-1 phase 1b/2a clinical tria

8 AL Amyloidosis patients relapsed/refractory to DARZALEX®-based regimens were treated with CAR-T NXC-201 100% (8/8) overall response rate and 63% (5...

May 21, 2023, 8:05 pm

Nexcella announces positive nxc-201 clinical results at asgct: 100% overall response rate in darzalex-relapsed/refractory al amyloidosis with zero icans in ongoing nexicart-1 phase 1b/2a clinical tria

8 AL Amyloidosis patients relapsed/refractory to DARZALEX®-based regimens were treated with CAR-T NXC-201 100% (8/8) overall response rate and 63% (5...

May 21, 2023, 8:05 pm

Nexcella announces positive nxc-201 clinical results at asgct: 100% overall response rate in darzalex-relapsed/refractory al amyloidosis with zero icans in ongoing nexicart-1 phase 1b/2a clinical tria

8 AL Amyloidosis patients relapsed/refractory to DARZALEX®-based regimens were treated with CAR-T NXC-201 100% (8/8) overall response rate and 63% (5...

May 21, 2023, 8:05 pm

Nexcella announces positive nxc-201 clinical results at asgct: 100% overall response rate in darzalex-relapsed/refractory al amyloidosis with zero icans in ongoing nexicart-1 phase 1b/2a clinical tria

8 AL Amyloidosis patients relapsed/refractory to DARZALEX®-based regimens were treated with CAR-T NXC-201 100% (8/8) overall response rate and 63% (5...

May 21, 2023, 8:05 pm

Immix biopharma announces positive nxc-201 clinical results at asgct: 100% overall response rate in darzalex-relapsed/refractory al amyloidosis with zero icans in ongoing nexicart-1 phase 1b/2a clinic

8 AL Amyloidosis patients relapsed/refractory to DARZALEX®-based regimens were treated with CAR-T NXC-201 100% (8/8) overall response rate and 63% (5...

May 21, 2023, 8:00 pm

Immix biopharma announces positive nxc-201 clinical results at asgct: 100% overall response rate in darzalex-relapsed/refractory al amyloidosis with zero icans in ongoing nexicart-1 phase 1b/2a clinic

8 AL Amyloidosis patients relapsed/refractory to DARZALEX®-based regimens were treated with CAR-T NXC-201 100% (8/8) overall response rate and 63% (5...

May 21, 2023, 8:00 pm

Immix biopharma announces positive nxc-201 clinical results at asgct: 100% overall response rate in darzalex-relapsed/refractory al amyloidosis with zero icans in ongoing nexicart-1 phase 1b/2a clinic

8 AL Amyloidosis patients relapsed/refractory to DARZALEX®-based regimens were treated with CAR-T NXC-201 100% (8/8) overall response rate and 63% (5...

May 21, 2023, 8:00 pm

Immix biopharma announces positive nxc-201 clinical results at asgct: 100% overall response rate in darzalex-relapsed/refractory al amyloidosis with zero icans in ongoing nexicart-1 phase 1b/2a clinic

8 AL Amyloidosis patients relapsed/refractory to DARZALEX®-based regimens were treated with CAR-T NXC-201 100% (8/8) overall response rate and 63% (5...

May 21, 2023, 8:00 pm

Stock market this week: q4 results, us debt ceiling talks, other factors that could drive equities this week

Stock markets witnessed an unpredictable movement last week mainly driven by Fii inflows quarterly earn...

May 21, 2023, 11:14 am

Huntington ingalls: a deep-value defense stock

Huntington Ingalls Industries is a value stock with an implied 2024 free cash flow yield of almost 10%, benefiting investors with a healthy balance sh...

May 21, 2023, 5:55 am

Sovereign gold bond: price for premature redemption of series viii of sgb 2017-18 due on may 20

The RBI has set up a price for early redemption of Series ViiI of SGB 2017-18. This series was introduc...

May 20, 2023, 11:14 am

Rosen, global investor counsel, encourages allbirds, inc. investors with losses to secure counsel before important deadline in securities class action – bird

NEW YORK, May 19, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of: (i) Allbirds, Inc. (NASDAQ:...

May 20, 2023, 1:48 am


Search within

Pages Search Results: